This study shows vildagliptin reduces liver damage in rats with bisphenol-A exposure, suggesting a potential treatment for hepatic injury.
Bisphenol-A (BPA) is an environmental pollutant that causes hepatic injury. The antioxidant activity of vildagliptin is confirmed. The present study investigated the protective effect of Vildagliptin against BPA-induced hepatotoxicity. Twenty four rats were divided randomly into 4 groups (6 rats/group): A control group, BPA group, BPA + Vildagliptin group and Vildagliptin group. All rats, except the controls were orally administered 30 mg/kg body weight BPA and/or 10 mg/kg Vildagliptin. AST, ALT, Triglycerides and albumin were measured in the serum. MDA, GPX, XBP1, Caspase 3 and BCL2 were measured in liver tissues. BPA group showed a significant decrease of albumin and GPX and a significant increase of triglycerides, AST, ALT and MDA. BPA caused up regulation of caspase3 and XBP1 while caused down regulation of BCL2. The co-administration of Vildagliptin reversed these hazards. The results of this study established the protective effect of Vildagliptin against BPA induced liver dysfunction.
No takes yet. Share an insight, caveat, or question.
Elazeem et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: